NanoVibronix Advances UroShield® Trial and Receives Nasdaq Extension

NanoVibronix ( (NAOV) ) has provided an announcement.

NanoVibronix has completed the first phase of a randomized control trial for its UroShield® device at the University of Michigan, focusing on its potential to improve quality of life for patients with long-term catheter use. The company also received a limited extension from Nasdaq to meet listing requirements, contingent on demonstrating compliance with bid price and equity rules through measures such as a reverse stock split. Failure to comply may lead to delisting, affecting capital-raising abilities.

More about NanoVibronix

NanoVibronix, Inc. is a medical device company based in Tyler, Texas, with research and development operations in Nesher, Israel. The company specializes in developing therapeutic devices using patented low-intensity surface acoustic wave (SAW) technology, primarily targeting applications such as biofilm disruption, bacterial colonization control, and pain relief. Its main products include PainShield® and UroShield®, designed for home or care setting use.

YTD Price Performance: -3.06%

Average Trading Volume: 406,625

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $2.26M

Learn more about NAOV stock on TipRanks’ Stock Analysis page.